Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business ProgressBusiness Wire • Friday
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to DeclineZacks Investment Research • Tuesday
Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-TermZacks Investment Research • Monday
Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-TermZacks Investment Research • 10/23/26
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock RisesZacks Investment Research • 08/20/26
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business ProgressBusiness Wire • 08/06/26
Top Healthcare Stocks Beyond The Market Rotation Averaging 128% Forward EPS GrowthSeeking Alpha • 07/24/26
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus NephritisBusiness Wire • 07/06/26
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and MarkerZacks Investment Research • 06/26/26
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 MillionThe Motley Fool • 06/07/26
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or DeathBusiness Wire • 06/04/26
Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks TranscriptSeeking Alpha • 06/03/26
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top EstimatesZacks Investment Research • 05/07/26
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business ProgressBusiness Wire • 05/07/26
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value RightBusiness Wire • 03/30/26